[1]蒋玉欢,何本超,郑志刚,等.改良Miccoli微创术联合术后DC-CIK治疗甲状腺癌疗效及对患者血清Gal-3、sIL-2R水平的影响[J].陕西医学杂志,2020,49(11):1417-1421.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.012]
　JIANG Yuhuan,HE Benchao,ZHENG Zhigang,et al.Curative effect of modified Miccoli minimally invasive surgery combined with postoperative DC-CIK in the treatment of thyroid cancer and its effect on patients' serum Gal-3 and Sil-2R levels[J].,2020,49(11):1417-1421.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.012]
点击复制

改良Miccoli微创术联合术后DC-CIK治疗甲状腺癌疗效及对患者血清Gal-3、sIL-2R水平的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年11期
页码:
1417-1421
栏目:
临床研究
出版日期:
2020-11-05

文章信息/Info

Title:
Curative effect of modified Miccoli minimally invasive surgery combined with postoperative DC-CIK in the treatment of thyroid cancer and its effect on patients' serum Gal-3 and Sil-2R levels
作者:
蒋玉欢; 何本超; 郑志刚; 陈绪清; 胡 敏△
湖北省天门市第一人民医院(湖北省科技学院附属医院)耳鼻咽喉头颈外科(天门 431700)
Author(s):
JIANG Yuhuan; HE Benchao; ZHENG Zhigang; et al.
Department of Otorhinolaryngology Head and Neck Surgery,First People's Hospital of Tianmen City,Hubei Province(Affiliated Hospital of Hubei University of Science and Technology)(Tianmen 431700)
关键词:
改良Miccoli微创术;  DC-CIK治疗;  甲状腺癌;  临床疗效;  免疫治疗;  血清指标
Keywords:
Modified Miccoli minimally invasive surgery;  DC-CIK therapy;  Thyroid cancer;  Clinical efficacy;  Immunotherapy;  Serum index
分类号:
R736.1
DOI:
DOI:10.3969/j.issn.1000-7377.2020.11.012
文献标志码:
A
摘要:
目的:探究改良Miccoli微创术联合术后树突状细胞-细胞因子诱导杀伤细胞(DC-CIK)治疗对甲状腺癌疗效及血清Gal-3、sIL-2R水平的影响。方法:将62例甲状腺癌治疗患者为研究对象,按照随机数字表法分为联合治疗组和手术治疗组,每组36例,手术治疗组患者仅采用改良的Miccoli微创手术进行治疗,联合治疗组则采用改良的Miccoli微创手术联合DC-CIK免疫疗法治疗,考察两组患者的临床疗效,治疗前及治疗2个月后,记录两组患者的Cyfra 21.1、sIL-2R和Gal-3等肿瘤指标水平和CD4+ Th17、CD4+CD+ 25Treg 及Th17/Treg免疫指标水平。记录两组患者治疗6个月内的并发症发生情况。结果:治疗2个月后,联合治疗组有效率为88.89%,手术治疗组有效率为63.89%,联合治疗组临床有效率明显优于手术治疗组(P<0.05); 治疗后,联合治疗组的Cyfra 21.1和Gal-3水平明显高于手术治疗组(P<0.05),sIL-2R水平明显低于手术治疗组,差异具有统计学意义(P<0.05); 较之于手术治疗组,联合治疗组的CD4+CD+25Treg 及Th17/Treg水平更高,CD4+ Th17水平明更低,差异具有统计学意义(P<0.05); 手术治疗组喉上、喉返神经麻痹、甲状旁腺功能障碍、肿瘤复发等并发症发生率为16.67%,联合治疗组为2.78%,两组比较差异有统计学意义(P<0.05)。结论:对甲状腺癌患者采用改良Miccoli微创术联合术后DC-CIK治疗能显著抑制患者病情,改善其不良预后。
Abstract:
Objective:To explore the curative effect of modified Miccoli minimally invasive surgery combined with postoperative dendritic cell-cytokine-induced killer cell(DC-CIK)in the treatment of thyroid cancer and its effect on patients' serum Gal-3 and sIL-2R levels.Methods:62 patients with thyroid cancer treated were selected and divided into combined treatment group and surgical treatment group according to a random number table,with 36 cases in each group.The surgical treatment group were treated with only modified Miccoli minimally invasive surgery,and the combined treatment group was treated with modified Miccoli minimally invasive surgery combined with DC-CIK immunotherapy.The clinical efficacy of the two groups of patients was investigated.Before treatment and 2 months after treatment,the levels of Cyfra 21.1,sIL-2R,Gal-3 CD4+ Th17,CD4+CD+ 25Treg and Th17/Treg of the two groups were recorded.The complications of the two groups of patients within 6 months of treatment were recorded.Results:After 2 months of treatment,the effective rate of the combined treatment group was 63.89%,the effective rate of the surgical treatment group was 88.89%,and the clinical effective rate of the combined treatment group was significantly better than that of the surgical treatment group(P<0.05).After treatment,Cyfra 21.1 and Gal-3 levels in the combined treatment group were significantly higher than those in the surgical treatment group(P<0.05),and sIL-2R level was significantly lower than that in the surgical treatment group(P<0.05).Compared with the surgical treatment group,CD4+CD+ 25Treg and Th17/Treg levels in the combined treatment group were higher,and CD4+ Th17 level was lower(P<0.05).The incidence of complications such as superior laryngeal palsy,recurrent laryngeal nerve palsy,parathyroid dysfunction and tumor recurrence was 16.667% in the surgical treatment group and 2.78% in the combined treatment group,with statistically significant difference(P<0.05).Conclusion:Modified Miccoli minimally invasive surgery combined with postoperative DC-CIK treatment for patients with thyroid cancer can significantly inhibit the patient's condition and improve its poor prognosis.

参考文献/References:

[1] Jr WS,Tarbell NJ,Min Y,et al.Thyroid cancer[J].Clinical Radiation Oncology,2017,347:346-347.
[2] Zou ZW,Liu T,Li Y,et al.Melatonin suppresses thyroid cancer growth and overcomes radioresistance via inhibition of p65 phosphorylation and induction of ROS[J].Redox Biology,2018,16(7):226.
[3] Papaleontiou M,Hughes DT,Guo C,et al.Population-based assessment of complications following surgery for thyroid cancer[J].Journal of Clinical Endocrinology & Metabolism,2017,102(7):244-247.
[4] 杨 杨,徐 泉,张 菁,等.高频彩色多普勒超声对甲状腺髓样癌的诊断价值[J].陕西医学杂志,2017,46(12):1709.
[5] Yu H,Ge X,Pan W,et al.Modified Miccoli's thyroid surgery for thyroid diseases[J].Molecular & Clinical Oncology,2015,3(5):1014.
[6] 田 萍,郑 玲.恶性黑色素瘤的基因靶向治疗及生物免疫治疗的研究现状[J].实用药物与临床,2017,20(5):593-597.
[7] Wang B.Short-term curative efficacy of DC-CIK cell-therapy on patients with advanced non-small cell lung cancer[J].Journal of Modern Oncology,2014,23(18):119-123.
[8] 汤钊猷.现代肿瘤学[M].北京:人民卫生出版社,2000:166.
[9] 孙嘉伟,许晓君,蔡秋茂,等.中国甲状腺癌发病趋势分析[J].中国肿瘤,2013,22(9):690-693.
[10] 刘 南,曾庆东.Miccoli甲状腺手术的发展及现状[J].腹腔镜外科杂志,2017,22(4):246-248.
[11] Shi G,Dong M,Ren Y,et al.Modified Miccoli's approach versus total endoscopic approach for benign thyroid nodules[J].Chinese Journal of General Surgery,2014,23(5):643-646.
[12] 周世繁.DC-CIK细胞联合化疗对晚期非小细胞肺癌患者免疫功能的影响[J].海南医学院学报,2017,23(4):510-513.
[13] 顾大力,沈 祥.改良Miccoli微创甲状腺手术治疗甲状腺癌的临床研究[J].医学临床研究,2016,33(11):2168-2170.
[14] Qu HQ,Zhou XS,Zhou XL,et al.Effect of DC-CIK cell on the proliferation,apoptosis and differentiation of leukemia cells[J].Asian Pacific Journal of Tropical Medicine,2014,7(8):659-662.
[15] 王文涛,张国俊.CEA、CYFRA21-1、NSE、CA125联合检测在肺癌诊断中的价值[J].中国实验诊断学,2014,18(2):224-226.
[16] 张彭南,孙 红.半乳糖凝集素-3(Gal-3)在上皮性卵巢癌中的表达及其对增殖、迁移和侵袭的影响[J].复旦学报:医学版,2014,41(3):321-327.
[17] 孔春雨,吴 梅.叶酸联合气滞胃痛颗粒对Hp阳性慢性萎缩性胃炎患者血清胃泌素、sIL-2R及免疫功能影响[J].中国生化药物杂志,2015,35(7):101-103.
[18] 韩 策,尤向辉,聂 娜,等.肿瘤免疫治疗研究进展[J].陕西医学杂志,2015,44(4):502-503.

更新日期/Last Update: 2020-11-05